Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > TRAIL R2


Brief Information

Name:Tumor necrosis factor receptor superfamily member 10B
Target Synonym:Tumor necrosis factor receptor superfamily member 10B,CD262,DR5,KILLER,TRAILR2,Death receptor 5,TRAIL-R2,UNQ160/PRO186,TNFRSF10B,TNF Receptor Superfamily Member 10b,TNF-Related Apoptosis-Inducing Ligand Receptor 2,TRICK2,ZTNFR9,P53-Regulated DNA Damage-Inducible Cell Death Receptor(Killer),Tumor Necrosis Factor Receptor-Like Protein ZTNFR9,Death Domain Containing Receptor For TRAIL/Apo-2L,Apoptosis Inducing Protein TRICK2A/2B,Apoptosis Inducing Receptor TRAIL-R2,Cytotoxic TRAIL Receptor-2,Fas-Li
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:11
Lastest Research Phase:Approved

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data


Loaded Human TRAIL R2, Fc Tag (Cat. No. TR2-H5255) on AHC Biosensor, can bind Human TRAIL, His Tag with an affinity constant of 0.146 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).


Immobilized Human TNFSF10 at 2 μg/mL (100 μL/well) can bind Mouse TRAIL R2, His Tag (Cat. No. TR2-M52H5) with a linear range of 0.039-0.625 μg/mL (QC tested).

Synonym Name



Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B) is also known as TNF-related apoptosis-inducing ligand receptor 2 (TRAILR2), Death receptor 5 (DR5), CD262, KILLER, is a member of the TNF-receptor superfamily, and contains an intracellular death domain.  TNFRSF10B / DR-5 is widely expressed in adult and fetal tissues; very highly expressed in tumor cell lines. TRAILR2 / CD262 / DR5 is the receptor for the cytotoxic ligand TNFSF10/TRAIL. The adapter molecule FADD (a death domain containing adaptor protein) of TRAIL-R2 / TNFRSF10B recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. CD262 / DR5 Promotes the activation of NF-kappa-B. DR5 is essential for ER stress-induced apoptosis and is regulated by p53/TP53.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Aponermin Approved Beijing Shadong Biotech Co Ltd 沙艾特 Mainland China Multiple Myeloma Wuhan Hiteck Biological Pharma Co Ltd 2023-11-02 Multiple Myeloma Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Dulanermin (Shanghai GeBaiDe) Phase 3 Clinical Shanghai Gebaide Biotechnology Co Ltd Carcinoma, Non-Small-Cell Lung Details
Recombinant human tumor necrosis factor-related apoptosis-inducing ligand (Shenzhen Xinpeng Biotech) Phase 3 Clinical Shenzhen Sinobioway Xinpeng Biomedicine Co Ltd Neoplasms Details
Conatumumab AMG-655 Phase 2 Clinical Amgen Inc Ovarian Neoplasms; Solid tumours; Rectal Neoplasms; Carcinoid Tumor; Pancreatic Neoplasms; Colonic Neoplasms; Neoplasms; Sarcoma; Colorectal Neoplasms; Lymphoma; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis Details
Anti-DR5 CAR-T cell therapy (Shenzhen BinDeBio) Phase 2 Clinical Shenzhen Bindebio Ltd Esophageal Neoplasms; Stomach Neoplasms; Glioma; Carcinoma, Hepatocellular Details
Rilunermin alfa SCB-313 (TRAIL-Trimer) Phase 1 Clinical Sichuan Sanyecao Bio-Pharmaceutical Co Ltd Hydrothorax; Ascites; Peritoneal Neoplasms; Pleural Effusion, Malignant Details
BI-905711 BI-905711 Phase 1 Clinical Boehringer Ingelheim Gmbh Pancreatic Neoplasms; Cholangiocarcinoma; Gastrointestinal Neoplasms Details
Recombinant anti-human DR5 monoclonal antibody (Lonn Ryonn Pharma) CTB-006 Phase 1 Clinical Beijing Tongwei Shidai Shengwu Jishu Youxian Gongsi, Lonn Ryonn Pharma Ltd Solid tumours Details
Ozekibart JCT-205; INBRX-109 Phase 1 Clinical Inhibrx Inc Adenocarcinoma Details
Oba-01 Oba-01; Oba01 Phase 1 Clinical Yantai Heyuanaidisi Biomedical Technology Co Ltd Carcinoma, Non-Small-Cell Lung Details
DS-8273 DS-8273; DS-8273a Phase 1 Clinical Daiichi Sankyo Co Ltd Solid tumours; Colorectal Neoplasms; Lymphoma; Melanoma Details
Aplitabart IGM-8444 Phase 1 Clinical Igm Biosciences Inc Solid tumours; Chondrosarcoma; Sarcoma; Colorectal Neoplasms; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Leukemia, Lymphocytic, Chronic, B-Cell Details

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message